Generated by AI
argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on immunology medicines, including treatments for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. argenx also advances a broader pipeline of differentiated antibody therapeutics built on its proprietary Simple Antibody platform, which supports research across autoimmune and other specialty disease areas. As an ADR, it gives U.S. market participants a way to access argenx’s underlying equity exposure through a familiar U.S.-traded security. The asset is closely tied to the global biotechnology and healthcare markets, where demand for specialized biologic therapies continues to shape commercial and clinical activity.
WebsiteLaarderhoogtweg 25
Amsterdam, 1101 EB
Netherlands
The latest articles about ARGX.
Cradle, today announced that argenx is expanding use of Cradle's end-to-end AI-driven protein engineering platform to more scientists and antibody discovery programs following successful results from its initial work.
argenx is a Hold with its $550M Unnatural Products deal for an unproven pipeline that may pressure commercial products and R&D. Read more on ARGX stock here.
Summary of Oct 8's posts. Generated by AI.
No summary yet.
Summary of Dec 20's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Investors talking about ARGX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.